CME Group stock has delivered a 55.1% gain over the past five years, yet current valuation checks and pricing signals suggest the shares may now sit closer to fair value rather than being a clear bargain. Recent product launches and record activity in key contracts are drawing attention, while the intrinsic value estimate and market multiples offer a more restrained read on potential upside.

• A 55.1% return over five years points to solid long term wealth creation, which raises the bar for any new buyers looking for further gains from CME Group.
• Recent expansion in futures products, including single stock and 24/7 gold contracts, can support expectations for future fee based revenue, while questions around partnerships such as FanDuel highlight regulatory and reputational risks that may cap what investors are willing to pay.
• CME Group screens as overvalued on earnings based multiples and scores only 2 out of 6 on broader valuation checks, which suggests the stock leans expensive rather than clearly cheap at current levels.

For investors, the debate is whether CME Group's recent product momentum and long term share price gains are already fully reflected in today’s valuation, or if the intrinsic value estimate still leaves room for further upside.

Is CME Group Fairly Priced on Excess Returns?

The Excess Returns model looks at how efficiently CME Group turns its equity base into profits above the cost of capital and then capitalises those extra earnings. For CME Group, the key inputs are a Book Value of $73.82 per share and a Stable EPS estimate of $13.57 per share, based on weighted future Return on Equity forecasts from 5 analysts.

These earnings are compared with a Cost of Equity of $6.55 per share, which implies an Excess Return of $7.02 per share on an Average Return on Equity of 16.12%. The model also assumes a Stable Book Value of $84.19 per share, sourced from 3 analyst estimates. Putting these together gives an intrinsic value of $249.90 per share. With the shares trading about 5.1% above that figure, the model indicates CME Group is slightly overvalued rather than clearly cheap. The launch of single stock futures and 24/7 products helps explain why the market is comfortable paying a premium for this earnings profile.

On the Excess Returns model, CME Group stock screens as roughly fairly valued, with only a mild tilt toward being overvalued at today’s price.

CME Group is fairly valued according to our Excess Returns, but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Does CME Group Look Pricey on Earnings?

The P/E multiple suits CME Group because earnings are a core focus for investors in established exchanges and market infrastructure companies. CME Group currently trades on a P/E of 22.1x, which sits below the wider Capital Markets industry average of 39.0x and also below a peer group average of 25.5x.

However, the tailored fair P/E ratio for CME Group is 16.1x, based on its earnings profile, business mix and risk assumptions. That means the stock trades on a premium of roughly 6 turns of earnings to what this framework suggests is appropriate, even with interest in new products such as single stock futures and 24/7 contracts. On this view, CME Group does not screen as a bargain simply because its P/E is lower than the industry headline figure.

On the preferred P/E yardstick, CME Group stock appears expensive compared with the fair multiple implied by its fundamentals.

The CME Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for CME Group pick up where the valuation work leaves off and explain what future growth, margins and earnings would need to look like for the stock to be worth materially more or less than today’s price. Each one sets out CME Group's fair value as a clear thesis about the business that you can track over time, rather than a single static number, and they appear on Simply Wall St's Community page.

Be one of the first voices in the Simply Wall St community to set out a clear, number driven narrative on whether CME Group's recent product launches, including single stock and 24/7 gold futures, support today’s share price. Share a view that others can follow over time and see how your thesis holds up as new results and contract activity come through.

Do you think there's more to the story for CME Group? Head over to our Community to see what others are saying!

The Bottom Line

CME Group now appears roughly fully valued according to the Excess Returns intrinsic value estimate, with the share price sitting modestly above that figure. The tailored P/E framework also points to an overvalued reading, which is consistent with the low overall value score. For you, the key question is whether CME Group can continue to justify a premium multiple through resilient fee based earnings from its newer products, or whether enthusiasm fades and the valuation settles closer to the implied fair P/E over time.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.